Company news

MetaVia Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

March 20, 2025

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

January 9, 2025

MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

December 18, 2024

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

December 17, 2024

MetaVia to Present at the Emerging Growth Conference in December

December 1, 2024

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

November 17, 2024

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

November 12, 2024

NeuroBo Pharmaceuticals to Present at the November 21st Virtual Investor Summit Microcap Event

November 10, 2024

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

September 30, 2024

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

September 29, 2024

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 13, 2024

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

August 5, 2024

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

July 29, 2024

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

July 10, 2024

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

June 25, 2024

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 23, 2024

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

May 21, 2024

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

April 29, 2024

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

April 16, 2024

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

March 31, 2024

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

March 27, 2024

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

March 3, 2024

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

February 28, 2024

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

February 11, 2024

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

January 31, 2024

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

January 17, 2024

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

January 8, 2024

NeuroBo to Participate in Industry and Investor Conferences in January

January 1, 2024

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

December 27, 2023

NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split

December 18, 2023

NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 12, 2023

NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.

November 5, 2023

NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference

October 16, 2023

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

September 14, 2023

NeuroBo pharmaceuticals appoints hyung heon Kim as Chief Executive Officer and President

August 13, 2023

NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 8, 2023

NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

August 2, 2023

NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01

August 1, 2023

NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models

June 26, 2023

NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors

May 11, 2023

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

May 1, 2023

NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results

March 29, 2023

NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President

January 17, 2023

NeuroBo announces closing of $32.3 million underwritten public offering including full exercise of overallotment option and concurrent private placement

November 7, 2022

NeuroBo announces pricing of $30 million underwritten public offering and concurrent private placement

November 3, 2022

NeuroBo Pharmaceuticals, Inc. Compliant with All Applicable Nasdaq Listing Criteria

September 28, 2022

NeuroBo Pharmaceuticals Announces Reverse Stock Split

September 11, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 24 decks. Every deck is listed under its year.